Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares

Key Points

• Amneal Pharmaceuticals EVP Jason Daly sold 6,613 shares at an average price of $17.70, generating approximately $117,050. After the sale, Daly retained 245,171 shares, a 2.63% reduction in his position.
• AMRX shares fell 2.2% to $17.27, while the company’s market capitalization stood at approximately $5.51 billion. The stock has traded between $9.15 and $19.26 over the past 52 weeks.
• Analyst sentiment remains positive, with an overall “Buy” rating and a consensus price target of $17.67; UBS recently raised its target to $25, while Goldman Sachs maintained a $21 target.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Jason Daly sold 6,613 shares of Amneal Pharmaceuticals stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $17.70, for a total transaction of $117,050.10. Following the transaction, the executive vice president owned 245,171 shares in the company, valued at $4,339,526.70. The trade was a 2.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Amneal Pharmaceuticals Stock Down 2.2%

Amneal Pharmaceuticals stock traded down $0.39 during trading on Thursday, reaching $17.27. 2,244,096 shares of the company's stock were exchanged, compared to its average volume of 2,168,140. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.15 and a 52-week high of $19.26. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 35.24 and a beta of 1.27. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The company's 50-day moving average is $17.08 and its two-hundred day moving average is $14.54.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent research reports. The Goldman Sachs Group reiterated a "buy" rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Zacks Research raised Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 7th. UBS Group upped their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Weiss Ratings raised shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $17.67.

Institutional Trading of Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Intech Investment Management LLC raised its stake in Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company's stock valued at $1,229,000 after buying an additional 1,159 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Amneal Pharmaceuticals by 1.6% in the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company's stock worth $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Amneal Pharmaceuticals by 2.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company's stock valued at $859,000 after acquiring an additional 1,582 shares during the last quarter. Comerica Bank increased its holdings in shares of Amneal Pharmaceuticals by 56.1% in the 4th quarter. Comerica Bank now owns 4,690 shares of the company's stock valued at $59,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $26,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source